Terms: = Pancreatic cancer AND WT1, WAGR, 7490, ENSG00000184937, WT33, GUD, WIT-2 AND Prognosis
11 results:
1. Baseline immunity predicts prognosis of pancreatic cancer patients treated with wt1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.
Ota S; Miyashita M; Yamagishi Y; Ogasawara M
Hum Vaccin Immunother; 2021 Dec; 17(12):5563-5572. PubMed ID: 34919493
[TBL] [Abstract] [Full Text] [Related]
2.
Deng J; Zhang J; Ye Y; Liu K; Zeng L; Huang J; Pan L; Li M; Bai R; Zhuang L; Huang X; Wu G; Wei L; Zheng Y; Su J; Zhang S; Chen R; Lin D; Zheng J
Cancer Res; 2021 Oct; 81(20):5268-5283. PubMed ID: 34362795
[TBL] [Abstract] [Full Text] [Related]
3. Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2021 Aug; 25(4):415-424. PubMed ID: 33886156
[TBL] [Abstract] [Full Text] [Related]
4. MicroRNA-216a targets wt1 expression and regulates KRT7 transcription to mediate the progression of pancreatic cancer-A transcriptome analysis.
Wang W; Wang J; Yang C; Wang J
IUBMB Life; 2021 Jun; 73(6):866-882. PubMed ID: 33759343
[TBL] [Abstract] [Full Text] [Related]
5. Desmoplastic Small Round Cell Tumor of pancreatic Origin in a Young Child: A Case Report and Review of Literature.
Saleh D; Al-Maghrabi S; Al-Maghrabi H; Al-Maghrabi J
Am J Case Rep; 2020 Jul; 21():e922762. PubMed ID: 32655125
[TBL] [Abstract] [Full Text] [Related]
6. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue.
Zhou Q; Andersson R; Hu D; Bauden M; Kristl T; Sasor A; Pawłowski K; Pla I; Hilmersson KS; Zhou M; Lu F; Marko-Varga G; Ansari D
EBioMedicine; 2019 May; 43():282-294. PubMed ID: 30982764
[TBL] [Abstract] [Full Text] [Related]
7. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract] [Full Text] [Related]
8. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with wt1-targeted dendritic cell vaccines.
Hanada S; Tsuruta T; Haraguchi K; Okamoto M; Sugiyama H; Koido S
Hum Vaccin Immunother; 2019; 15(2):397-406. PubMed ID: 30230959
[TBL] [Abstract] [Full Text] [Related]
9. wt1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected pancreatic cancer in a Phase I Study.
Yanagisawa R; Koizumi T; Koya T; Sano K; Koido S; Nagai K; Kobayashi M; Okamoto M; Sugiyama H; Shimodaira S
Anticancer Res; 2018 Apr; 38(4):2217-2225. PubMed ID: 29599342
[TBL] [Abstract] [Full Text] [Related]
10. Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer.
Koido S; Okamoto M; Kobayashi M; Shimodaira S; Sugiyama H
Discov Med; 2017 Aug; 24(130):41-49. PubMed ID: 28950074
[TBL] [Abstract] [Full Text] [Related]
11. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma.
Terashima T; Mizukoshi E; Arai K; Yamashita T; Yoshida M; Ota H; Onishi I; Kayahara M; Ohtsubo K; Kagaya T; Honda M; Kaneko S
Cancer Immunol Immunother; 2014 May; 63(5):479-89. PubMed ID: 24633336
[TBL] [Abstract] [Full Text] [Related]
